Healthy Clinical Trial
Official title:
Smart Sleep In-home Validation Extension Study
Verified date | November 2018 |
Source | Philips Respironics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a nonrandomized, unblinded, uncontrolled case series clinical trial validating the SmartSleep product, including SleepMapper app in the home setting. It is intended to provide data related to product use and cognitive testing incorporating a longer baseline period for comparison purposes. It will include adults (21-50 yr. old) who are working full time and report shortened sleep due to lifestyle. For the purposes of this study, shortened sleep is defined as sleeping at least 5 hrs. of sleep per night, and sleeping less than or equal to 7 hrs. at least 3 nights per week. Participants also increase their sleep duration by ≥ 1 hour on the weekends. In addition, participants report a sleep latency ≤ 30 minutes less than or equal to 3 nights per week. Participants are generally healthy individuals who have not been diagnosed with any sleep-related medical conditions. In addition, participants diagnosed with major organ system diseases or requiring oxygen therapy are excluded from participation. Up to 75 individuals will be consented in order to complete a total of 50 participants using a nonrandomized design. The study involves an initial screening visit followed by home use of the SmartSleep device with SleepMapper app. The home use will include an initial week of baseline use followed by 3 weeks of use with boost on. Study staff will contact participants after the first week of use as a reminder. Participants will be asked to complete a battery of cognitive tests upon wake up each morning. Participants will be asked to complete a question twice daily during the home use period. Additional phone calls may occur on an as needed basis if issues arise. The final visit will be an in facility visit in which all study equipment will be returned. The anticipated study duration will be up to 6 weeks (including the 4 weeks of use period).
Status | Completed |
Enrollment | 61 |
Est. completion date | November 7, 2018 |
Est. primary completion date | November 7, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Able to provide informed consent - Live in the US - Able to read, write and speak English - Adult volunteers aged 21-50 - Smartphone owner (iOS 9+ or Android 5.0+ OS) - Access to home Wi-Fi for syncing of SmartSleep data and cognitive testing - Working full time schedule [Note: Full time is considered a 32 hour work week start time at 7am or later] - Suffer from short sleep due to lifestyle - Gets less than 7 hours of sleep at least 3 days a week (via self-report) - Get at least 5 hours of sleep per night 7 nights a week (via self-report) - Gets 1 extra hour of sleep on the weekends (via self-report of extended nightly sleep or daytime nap) Exclusion Criteria: - Individuals who self-report severe contact dermatitis or an allergy to silver - Diagnosed as having any of the following conditions (via self-report): - Sleep Apnea - Insomnia - Restless legs syndrome - Parasomnia - Epilepsy/Seizures - Diagnosed as having any major organ system disease such as congestive heart failure, neuromuscular disease, renal failure, cancer, chronic obstructive pulmonary disease, respiratory failure or respiratory insufficiency, or patients requiring oxygen therapy (via self-report) - High Risk of Obstructive Sleep Apnea (OSA) based on Questionnaire - Daily caffeine intake > 650 mg - History of moderate hearing loss (via self-report) - Currently working night shift or rotating shift - Head circumference <54 cm (21 in) or >66 cm (26 in) - Individuals who self-report taking longer than 30 minutes more than 3 times a week to fall asleep once they turn lights off - Individuals who self-report regularly taking sleeping pills (more than once per week), including prescription or over the counter (OTC) pills such as Ambien, Tylenol PM or Zzzquil - Pregnant (via self-report) - Employee of Philips or spouse of a Philips employee - Employee (or spouse of an employee) of a company that designs, sells, or manufactures sleep-related products - Not able to comply with study procedures |
Country | Name | City | State |
---|---|---|---|
United States | Florida Lung & Sleep Associates | Lehigh Acres | Florida |
Lead Sponsor | Collaborator |
---|---|
Philips Respironics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The effects of the auditory stimulation delivered by the SmartSleep device in adults with shortened sleep schedules due to lifestyle as determined by changes in the cumulative (CSWA) or average slow-wave activity. | Efficacy will be evaluated based on the average of seven nights of use collecting baseline data compared to the average of twenty one nights of active SmartSleep, while in the home setting. SWA accumulation over Non-Rapid Eye Movement (NREM) sleep (CSWA) will be analyzed for each night in the active condition using as reference the average CSWA across baseline nights. | 4 weeks | |
Secondary | Change in performance of the Matrix reasoning task (MRT) correlated to the changes in CSWA over the trial period. | Performance of the MRT during baseline and active use weeks of the SmartSleep Device will be compared to changes in CSWA over the trial period. | 4 weeks | |
Secondary | Change in performance of the Digital Symbol Substitution Task (DSST) correlated to the changes in CSWA over the trial period. | Performance of the DSST during baseline and active use weeks of the SmartSleep Device will be compared to changes in CSWA over the trial period. | 4 weeks | |
Secondary | Change in performance of the Psychomotor Vigilance Testing -Brief (PVT) correlated to the changes in CSWA over the trial period. | Performance of the PVT during baseline and active use weeks of the SmartSleep Device will be compared to changes in CSWA over the trial period. | 4 weeks | |
Secondary | Change in sleepiness/alertness as measured by a 7 point scale correlated to the changes in CSWA over the trial period. | Change in sleepiness/alertness as measured by a 7 point scale during baseline and active use weeks of the SmartSleep Device will be compared to changes in CSWA over the trial period. | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |